HeyJaredHeme Onc Trial Files
Free monthly newsletter that summarizes the most significant, practice-changing heme-onc randomized controlled trials, straight to your inbox.
- Indexed issues, last 90 days
- 3
- Latest publication
- Sep 11, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 17, 2026
Latest issues
Heme Onc Trial Files Throwback Thursday: Rituximab + Chlorambucil in MALT Lymphoma, Rituximab Maintenance vs. Retreatment in FL (RESORT), and Long-Term Rituximab Maintenance in FL (PRIMA) (opens the original)
Read excerpt
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab MonotherapyZucca E et al. Journal of Clinical Oncology (March 2017)Bottom Line: This randomized phase III trial (IELSG-19) evaluated chlorambucil alone, rituximab alone, or their combination as first-line treatment for patients with extranodal marginal zone lymphoma of mucosa-associ
Heme Onc Trial Files: tafa-len-R-CHOP in High-Risk DLBCL, Pirtobrutinib vs. Ibrutinib in CLL, and Pola-R-GemOx in Relapsed DLBCL (opens the original)
Read excerpt
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND)Lenz G et al. The Lancet (June 2026)Bottom Line: This phase 3, randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide added to R-CHOP (tafa-len-R-CHOP) versus R-CHOP in 899 patients aged 18–80 years with previously untreated high-intermediate-risk or high-risk DLBCL or HGBL. The primary outcome was investigator-ass
Heme Onc Trial Files Throwback Thursday: BTK Inhibitors, Acalabrutinib + ASCT, and Acalabrutinib + BR in Mantle Cell Lymphoma (opens the original)
Read excerpt
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE)Dreyling M et al. The Lancet (May 2024)Bottom Line: This open-label, randomized phase 3 trial (TRIANGLE) enrolled 870 patients aged 18–65 years with previously untreated mantle cell lymphoma to compare standard immunochemotherapy plus autologous stem-cell transplantat
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.